Table 1.
Characteristics of NK cell donor breast cancer patients
| Age | Pathological type | ER | PR | HER2 | Ki-67 (%) | Length of illness | Therapy | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Chemotherapy | Radio therapy | Hormonal therapy | Trastuzumab | ||||||||
| 1 | 82 | IDC | - | - | - | +70 | 27 | 3*T+3*FEC | - | - | - |
| 2 | 51 | IDC | + | + | - | +40 | 23 | 1*X | + | Letrozole | - |
| 3 | 42 | ILC | + | + | - | +5 | 52 | 6*CAF | - | Tamoxifen | - |
| 4 | 55 | IDC | - | - | - | < 70 | 11 | 1*TAC+4*AC-T | - | - | - |
| 5 | 48 | IDC | - | - | + | +70 | 14 | 1*AC+5*TCH | - | - | + |
| 6 | 38 | IDC | - | - | + | +60 | 42 | 3*TC+3*NP | + | - | + |
| 7 | 71 | IDC | + | - | - | NA | 57 | 6*TAC | + | Tamoxifen | - |
| 8 | 62 | IDC | + | + | + | +25 | 52 | 3*AC-3*TH | - | Anastrozole | + |
| 9 | 59 | IDC | - | - | + | +60 | 39 | 6*TCH | + | - | + |
| 10 | 46 | IDC | + | + | + | +60 | 15 | 1*TAC+5*TCH | + | Tamoxifen | + |
| 11 | 49 | IDC | - | - | + | +70 | 10 | 4*AC-T | - | - | - |
| 12 | 48 | IDC | + | + | + | +40 | 29 | 6*TAC | + | Anastrozole | - |
| 13 | 44 | IDC | - | - | - | +70 | 27 | 3*T+3*FEC | - | - | - |
A, pirarubicin; C, cyclophosphamide; ER, estrogen receptor; E, epirubicin; F, fluorouracil; H, herceptin; HER2, human epidermal growth factor receptor 2; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; MC, medullary carcinoma; N, navelbine; P, Cisplatinum; PR, progesterone receptor; T, docetaxel/taxol; X, Xeloda. *All patients were female and had undergone surgery.